top of page

Exploring the Advantages


Traditional Probiotic Limitations with GEMM™

In a world where conventional probiotics often fall short, Melius MicroBiomics introduces a transformative solution: Genetically Engineered Microbial Medicines (GEMM™). Traditional probiotics face critical challenges, including inconsistent clinical evidence, lack of personalized approaches, and inadequate regulation. These issues become especially prominent in conditions involving inflammation, where standard probiotics struggle to survive and provide benefits. Our GEMMs are engineered to not only persist but also colonize in inflamed gut environments, overcoming the limitations of conventional probiotics.

Inconclusive evidence on probiotics in a clinical setting 

Currently, there are conflicting evidence regarding the benefits of probiotics in clinical settings.¹ ² In fact, a previous study identified a distinction between those who are either permissive or resistant, based on their native microbiome.³ Furthermore, significant interindividual variability exists in the human gut microbiome, particularly when considering global populations with diverse lifestyles. This variation in the gut microbiome highlights a necessity for more personalized probiotics, as current products typically offer standard strains to all consumers.


For patients being treated for conditions involving inflammation and oxidative stress, the evidence supporting efficacy of current probiotics is even less convincing. For instance, studies investigating the use of probiotics for inflammatory bowel disease (IBD) have shown no benefit in reducing remission in patients.

Inconsistent & inadequate methodologies in probiotic studies

The clinical studies on probiotics vary greatly methodologies, making it difficult to determine a consensus. Many of these studies rely on observational data such as subjective reports of the patient’s well-being, and even the quantitative often lacks significance.² Diverse combinations of strains used in these studies also make it difficult to assess their overall effectiveness.¹

Problem with Current Probiotics

Probiotics are bacteria that can provide beneficial health effects in their host. However, there are several concerns regarding the efficacy of probiotics, especially when in an inflamed gut.

Globally >48% of human commercialized products have fewer viable cells than claimed, and >40% are not even the microbial strains claimed.


Mazzantini, D., Calvigioni, M., Celandroni, F., Lupetti, A., & Ghelardi, E. (2021). Spotlight on the compositional quality of probiotic formulations marketed worldwide. Frontiers in microbiology, 12, 693973.

Beyond Probiotics

The GEMM™ Advantages

Our BioPersist™ and BioColonize™ technology developed at Melius MicroBiomics Inc. provides bacteria with unique properties that enhance bioavailability and clinical efficacy. Our genetic modification platforms enable bacteria to persist within and colonize in an inflamed gut, distinguishing them from conventional probiotics that often perish during inflammation, consequently diminishing their clinical efficacy in disease conditions.

Our goal is to integrate our patented technology into beneficial bacteria made specifically for its host. We aim to create Genetically Engineered Microbial Medicines (GEMM™) that are effective in treating diseases in humans, horse, pigs, cats and dogs.

Our GEMM™ Technology

At Melius MicroBiomics, our mission is to revolutionize microbiome-based therapy through the power of GEMM™. We strive to enhance medicine by offering personalized, cutting edge therapies that align with the patient’s unique microbiome. Our goal is to lead the way in microbiome-based medicine, offering better health outcomes and improving the quality of life for both humans and animals affected by these conditions.

Our Mission


Our GEMM™ Applications

bottom of page